Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) shot up 0% during mid-day trading on Friday . The company traded as high as $1.32 and last traded at $1.28. 1,423,304 shares traded hands during mid-day trading, a decline of 34% from the average session volume of 2,168,549 shares. The stock had previously closed at $1.28.

A number of research firms have issued reports on IDXG. ValuEngine upgraded Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th. Maxim Group began coverage on Interpace Diagnostics Group in a research note on Tuesday, August 15th. They issued a “buy” rating and a $5.00 target price on the stock.

Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings results on Thursday, August 10th. The business services provider reported ($0.65) EPS for the quarter. The business had revenue of $3.86 million for the quarter. Interpace Diagnostics Group had a negative net margin of 37.08% and a negative return on equity of 32.06%.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Sabby Management LLC purchased a new stake in shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned 2.39% of Interpace Diagnostics Group as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 7.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Interpace Diagnostics Group, Inc. (IDXG) Shares Up 0%” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.